ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly other Oncology medicines — U.S. revenue ($M) ($M)
Form 10-Q / 10-K Note 2 Disaggregated Revenue
Latest, FY2025
1,888
Period ended Dec 31, 2025
Change on a year earlier
+16.9%
1,615 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Oncology medicines — U.S. revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,888 | +16.9% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 1,615 | +25.4% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 1,288 | +80.5% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 713 | +494.0% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 120 | +157.7% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 46.6 | -58.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 111 | -44.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 201 | +14.9% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 175 | +662.4% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 22.9 | – | Form 10-K (filed 2019-02-19) ↗ |
Breakdown
What makes up other oncology medicines — u.s. revenue ($m)
Cite this data
StockData. (2026). Eli Lilly Other Oncology medicines — U.S. revenue ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_other_onc_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.